27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Leerink resumed coverage on GW Pharmaceuticals PLC (NASDAQ: GWPH) in anticipation of FDA approval for Epidiolex. Analyst Paul Matteis expressed an Outperform Rating, and set the firm’s price target at $162.
Matteis primarily cited the FDA’s pending approval of Epidiolex, and the firm’s confidence in the drug as the reason for his bullish resumption of coverage.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The analyst stated a 90 percent probability for FDA approval following three positive Phase III trials.
Looking forward, Matteis is also optimistic concerning a global launch for Epidiolex, which is currently being administered to more than 1,000 children affected by Dravet Syndrome, Lennox Gastaut Syndrome and refractory seizures.
The stock traded recently at $132.80 after opening at $134.81.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.